Thoracic Hodgkin Disease Imaging
No Results
No Results
processing….
Hodgkin disease is a cancer of the lymph system (a lymphoma) that is characterized by the presence of large, abnormal Reed-Sternberg cells in a background of lymphocytes, macrophages, fibroblasts, and granulocytes. Dr Thomas Hodgkin first described Hodgkin disease in 1832. [1, 2, 3, 4]
The lymphatic system is composed of lymph nodes, lymphatic channels, the spleen, bone marrow, and the thymus. Because the lymphatic system is located throughout the body, Hodgkin disease can start almost anywhere; however, in this article, only thoracic involvement is addressed.
During 2016, approximately 8000 to 8500 patients will have been diagnosed with Hodgkin lymphoma, and approximately 1120 patients will have died with this disease. [5]
CT scanning of the thorax, abdomen, and pelvis is performed for initial staging purposes. Compared with other methods, CT is more sensitive for detecting lymphadenopathy and extralymphatic involvement. CT scanning may be most useful for evaluating patients with lymphoma, because it can depict the lymph nodes in the chest, abdomen, and pelvis. [6, 7, 8]
Magnetic resonance imaging (MRI) is performed in patients with suggested chest wall involvement because it offers better tissue contrast. [9]
Ultrasonography and echocardiography are useful for detecting pericardial effusion and for directing lymph node biopsies and pleural interventions. [10]
Bone scanning is useful for evaluating bone involvement in Hodgkin disease. Gallium-67 (67 Ga) scans obtained at baseline, during therapy, and in the posttreatment period can help in differentiating active Hodgkin disease from nonactive Hodgkin disease. [11]
Positron emission tomography (PET) scanning with fluorodeoxyglucose (FDG) is most useful for detecting disease relapse. [12, 13, 14, 15, 16] If available, PET-CT is most often preferred.
Bilateral bone marrow aspirations and biopsies are performed to assess stage III or IV disease with associated symptoms (eg, fever, weight loss >10%, drenching night sweats). [17]
Other investigations are directed to a particular clinical problem. For example, a superior venacavogram is obtained if the patient has clinical findings of superior vena cava (SVC) syndrome. Immunoscintigraphy is used only on an experimental basis.
Radiography is available everywhere and is inexpensive; however, it is limited in the evaluation of soft-tissue involvement of the chest wall. Chest radiographs cannot be used to differentiate the various causes of lymph node enlargement.
CT scanning is now available widely, barring some developing countries. CT scans cannot be used to differentiate the various causes of lymph node enlargement or to determine whether tumor residue is active or inactive. [18]
MRI is still limited in its availability because of its high cost. Also, some patients are claustrophobic and cannot tolerate the MRI examination.
Ultrasonography is limited in the thorax, because air contained in the lungs is not a suitable window through which the ultrasonographic waves can travel.
Currently, PET-CT is widely accepted in developed countries, but this imaging modality has limited availability in developing countries, and the studies are expensive.
Radiologic characteristics of Hodgkin disease are depicted in the images below.
In the thorax, Hodgkin disease most commonly involves the mediastinum. The nodular sclerosing histologic subtype of Hodgkin disease is the most common form found in the thorax, and it has a predilection for the anterior mediastinum (especially the thymus). The diagnosis of Hodgkin disease must be based on tissue biopsy results, because treatment strategies are based on the histologic type, the stage of disease, and the age as well as performance status of the patient. Imaging is essential for tumor staging, for assessing the response to treatment, for diagnosing relapses, and for evaluating treatment-related disorders. [2, 19, 20, 21, 22, 23, 24]
Hodgkin disease is staged according to the guidelines set out by the Ann Arbor, Michigan, Conference. Some modifications were made to this classification at the Cotswolds, United Kingdom, meeting. [25] Staging of Hodgkin disease is important for planning effective treatment, for follow-up monitoring, and for comparing trial treatment plans available in various centers.
Staging is as follows:
Stage I – Involvement of a single lymph node region (I) or localized involvement of a single extralymphatic organ (IE)
Stage II – Involvement of 2 or more lymph node regions on the same side of the diaphragm (II) or localized involvement of a single extralymphatic organ or site and its regional lymph node or nodes, with or without involvement of the other lymph node region on the same side of the diaphragm (IIE)
Stage III – Involvement of lymph node regions on both sides of the diaphragm (III) with or without localized involvement of an associated extralymphatic organ or site (IIIE), with or without involvement of the spleen (IIIS), or with or without involvement of both (IIIE+S)
Stage IV – Disseminated/multifocal involvement of 1 or more extralymphatic organs, with or without associated lymph node involvement, or isolated extralymphatic organ involvement with distal nodal involvement
Bulk disease, or massive mediastinal disease, is defined as the ratio of the maximum transverse diameter of a mass to the internal transverse thoracic diameter being 0.33 or greater, as measured on chest radiographs at the T5-T6 vertebral disk level. Other authors have defined bulk disease as a lymph node mass measuring 10 cm or more in its greatest dimension. [26]
The presence of other symptoms (eg, fever, weight loss >10%, drenching night sweats) and bulk disease is associated with a worse prognosis for patients with clinical stage I or stage II Hodgkin disease.
Hodgkin disease commonly appears as intrathoracic disease. Posteroanterior (PA) and lateral chest radiographs are essential for clinical staging. Mediastinal adenopathy is the most common presentation, and direct extension of the disease can be detected on chest radiographs. Chest images also allow for the evaluation of complications related to chemotherapy and radiation therapy. In follow-up studies for recurrent disease, chest radiography is the primary imaging modality (along with history taking, physical examination, and laboratory investigations). [24]
Among patients with Hodgkin disease, 67-74% have abnormal radiographic findings at presentation. Among patients with abnormal radiographic findings on chest images, 90% have bilateral, asymmetrical nodal disease.
In Hodgkin disease, disease spreads contiguously along lymph node chains. Prevascular and paratracheal lymph nodes are most commonly affected. A single lymph node group is involved in only 15% of patients. Rarely, the posterior mediastinal or paracardiac lymph nodes are involved.
The internal mammary chain of lymph nodes can be enlarged, but not without involvement of other lymph nodes.
Chest radiographs can demonstrate either a single group with lymph node enlargement or a lobulated appearance resulting from multinodal involvement.
Calcification is very rarely seen in untreated lymphoma. [27]
Direct invasion of the lungs can occur in 15-40% of patients and is nearly always associated with hilar adenopathy. [28] Primary pulmonary involvement without hilar, mediastinal, or extrathoracic involvement is unusual; however, recurrent Hodgkin disease may appear in the absence of adenopathy (especially in nodular sclerosing Hodgkin disease).
Lung involvement can produce either ill-defined or well-defined nodules, which can be unilateral or bilateral. These nodules may cavitate. Lung involvement can also appear as consolidation.
Other findings in Hodgkin disease that can be detected on radiographs of the chest include pleural effusions and skeletal lesions. [11]
In Hodgkin disease, two thirds of bone lesions are of the mixed lytic and sclerotic variety, 10-15% are sclerotic alone, and a small percentage are lytic alone. Sclerotic lesions tend to be confined to the vertebrae, demonstrating the typical appearance of ivory vertebrae.
Anterior scalloping of vertebrae can be detected on lateral chest radiographs, especially in the lower thoracic region.
With chest radiographs, Hodgkin disease can be quantified by calculating the mediastinal mass ratio (the ratio of the maximum width of the mediastinum to the maximum transverse thoracic diameter at the level of the diaphragm), by finding a mediastinal mass larger than one third of the transverse thoracic diameter at the T4-T5 level, or by determining an absolute transverse mediastinal diameter of 10 cm. [29]
In follow-up imaging of mediastinal bulk disease, 60% of chest radiographs demonstrate findings of residual adenopathy after treatment. This residual adenopathy may not contain active disease and may represent only residual scarring, but these can be seen at long-term follow-up.
Knowledge of lymph node distribution and lymphatics in the thorax is important because mediastinal involvement of the lymph nodes is the most common manifestation of thoracic Hodgkin disease. A clear understanding of normal radiographic findings in chest radiography is pivotal to recognizing subtle enlargement of the lymph nodes. [2, 24]
On chest radiographs on the left side, the normal aortopulmonary window is slightly concave, straight, or invisible. Any departure should be viewed with suspicion, and further investigations are needed. In the prevascular area, adenopathy is the most common cause for convexity of the aortopulmonary bay toward the left lung.
On chest radiographs on the right side, the azygos node lies variably in relation to the azygos vein as the vein passes forward above the right bronchus to enter the superior vena cava (SVC). This node is the lowest member of the group of right paratracheal lymph nodes. Any convexity in this region that has a greater part of its curvature above the right main bronchus probably should be regarded as abnormal. Low right prevascular nodal enlargement also can distort this region.
Subcarinal lymph nodes are difficult to recognize until they are large. They can cause displacement of the azygoesophageal pleural reflection. Paravertebral adenopathy can be diagnosed by distortion of the paravertebral pleural reflections, which produces convexity toward the lungs.
Pericardiac and diaphragmatic lymph nodes can fill the cardiophrenic angle on posteroanterior (PA) chest radiographs. On lateral views, these may lie retrosternally or at the level of the inferior vena cava or phrenic nerve. Smaller lymph nodes in these areas may simulate a pericardiac fat pad.
On PA chest radiographs, internal mammary lymph nodes can produce ill-defined increased opacity lateral to the sternum when sufficiently enlarged. On lateral views, these can appear as anterior extrapleural masses against the chest wall.
Most of the time, sufficiently enlarged lymph nodes in the thorax can be detected on chest radiographs, but subtle enlargement can be missed; therefore, further imaging with CT scanning is warranted.
A confluence of pulmonary veins, especially on the right side, can be mistaken for subcarinal lymphadenopathy. Small pericardiac or diaphragmatic lymph nodes can mimic a fat pad. An enlarged azygos vein can mimic azygous adenopathy. When in doubt, repeat chest radiographs and use the Valsalva maneuver. All of these false-positive findings on chest radiography can be easily identified by performing CT.
Subtle enlargement of intrathoracic lymph nodes can be missed on chest radiographs, and its detection greatly depends on the observer’s experience, as well as the type of radiograph performed.
In conjunction with chest radiographs, CT scanning is useful for initial staging and follow-up monitoring of Hodgkin disease. Contrast-enhanced CT scanning of the thorax, abdomen, and pelvis is performed in all patients. Any suggestion of lymph node enlargement, as demonstrated on chest radiographs, is usually confirmed with CT scanning. [7, 30, 31]
CT scanning has the additional advantage of depicting other areas of lymph node enlargement that are not obvious on chest radiographs. Some areas of lymph node enlargement that are difficult to detect by using radiography include paracardiac, supradiaphragmatic, and internal mammary chain lymph nodes; these can be detected easily via CT scanning. The modality also helps in formulating treatment plans and radiation fields. [4, 6, 7, 30] CT scans depicting characteristics of Hodgkin disease are presented below.
Involvement of the lungs and pericardium can occasionally be detected on CT scans; these exclude treatment by radiation therapy.
CT size criteria for lymph node involvement in the mediastinum are well defined. According to the criteria, subcarinal, paracardiac, and retrocrural lymph nodes are considered enlarged if they are larger than 12, 8, and 6 mm in their short-axis diameter, respectively. The remaining lymph nodes in the body are considered enlarged if they are larger than 10 cm in their short-axis diameter. [29, 32, 33, 34]
On CT scans, lymph node enlargement can be seen as multiple, rounded soft-tissue masses or bulky soft-tissue masses caused by nodal aggregation. Usually, a homogeneous soft-tissue mass is noted; it may be heterogeneous when it is large, with areas of low attenuation representing necrosis, hemorrhage, or cyst formation. [35]
In rare cases, calcification can be seen in the lymph nodes on pretreatment scans.
A discrete or infiltrating thymic mass can be seen.
Associated findings that can be detected on CT scans include mediastinal displacement, compression, and invasion of the vascular structures, pericardium, heart, pleura, lungs, and chest wall.
CT scanning is used during surveillance to detect local and distant recurrences of the disease. Recurrent lymphoma has an appearance similar to that of primary Hodgkin lymphoma; however, pulmonary parenchymal involvement is much more common in recurrent Hodgkin lymphoma. Parenchymal involvement may present as a pulmonary nodule or a mass, lobar or segmental consolidation with air bronchogram, and a reticular pattern with peribronchovascular and interlobular septal thickening. [36]
Recurrence within the radiation field usually presents as an alteration in the contour of the radiation fibrosis, with increase in size, convex borders, and obliteration of the air bronchograms with homogeneous opacity, and filling of the bronchi. [37]
Posttreatment radiation fibrosis usually develops 6-12 months after completion of radiation. The features include a well-demarcated area of volume loss, linear scarring or consolidation, parenchymal distortion and traction bronchiectasis, ipsilateral mediastinal shift, and adjacent pleural thickening. [37, 38]
Bleomycin-induced lung toxicity can present as diffuse alveolar damage, nonspecific interstitial pneumonitis, and bronchiolitis obliterans organizing pneumonia. Cyclophosphamide can cause pulmonary hemorrhage and diffuse alveolar damage. Nonspecific interstitial pneumonitis may present as ground-glass opacities combined with reticular opacities in peripheral subpleural distribution.
Bronchiolitis obliterans organizing pneumonia usually presents as bilateral, asymmetric ground-glass opacities or air-space consolidations in the peripheral or peribronchial distribution. [39, 40]
Patients who have been treated for Hodgkin lymphoma have an increased risk of lung cancer and mesothelioma, and CT is the primary imaging modality for both of these.
CT scans can help in the differentiation of the various causes of mediastinal or hilar enlargement seen on chest radiographs in most patients; however, CT is limited in detecting chest wall invasion (in which case, MRI is the modality of choice). CT is limited in the use of size criteria for lymph node involvement, because nodes that are larger than those defined by the criteria can be reactive without tumor involvement. Also, lymph nodes smaller than those defined by the size criteria can harbor Hodgkin disease. Residual masses can persist during and after treatment without any viable tumor being present. [30, 6]
CT scans cannot help in differentiating between fibrosis and viable tumor. MRI, gallium scanning, or PET scanning can be used to identify residual tumor and predict the patient’s response to therapy. [41, 42, 43, 44, 45]
MRI is not the primary modality for evaluating Hodgkin disease, but its use is important in the pediatric population to avoid radiation exposure. Multiplanar capability, high tissue contrast, flow sensitivity, and the use of gadolinium-based contrast agents all make MRI an ideal tool for problem solving. Its soft-tissue contrast and multiplanar capability also make it useful for assessing chest wall invasion, pericardial involvement, pleural involvement, and brachial plexus involvement. [4]
In thoracic lymphomas, MRI is used to image suggestive spinal cord compression, involvement of the spinal cord and the meninges, involvement of the musculoskeletal system in the chest, cardiac involvement, and involvement of the brachial plexus.
MRI is also helpful in posttreatment evaluation to differentiate between fibrosis and tumor. [18]
On MRI, lymph node involvement is defined by size criteria similar to those of CT.
MRI is helpful for planning radiation therapy fields because of its multiplanar capabilities. [41]
On T1-weighted images, tumor involvement can be seen as relatively homogeneous masses with low signal intensity (similar to that of muscle).
On T2-weighted images, high signal intensity equal to or slightly greater than that of fat can result from tumoral edema, inflammation, immature fibrosis, or granulomatous tissue. Follow-up T2-weighted images can show signal intensity increased from the baseline. This finding is correlated with disease recurrence.
Low signal intensity on posttherapeutic T2-weighted images rules out the possibility of relapse in most patients. Increased signal intensity on T2-weighted images obtained within 6 months of therapy is nonspecific; however, after 6 months, this finding suggests recurrent disease. [45]
An enlarging or new mass may represent recurrent disease, a posttherapeutic thymic cyst, or thymic hyperplasia. [19]
Overall, the accuracy of MRI for predicting disease recurrence is similar to that of gallium scintigraphy. [43]
Dense fibrosis may demonstrate low signal intensity on T2-weighted images.
MRI has a role in identifying areas of bone marrow abnormality for targeting bone marrow biopsies; however, MRI is not a replacement for bone marrow biopsy in pathologic staging. [46]
Diffusion weighted imaging (DWI) is a newer functional MRI technique, depicting differences in the mobility of water in the tissues. This technique has been emerging as a radiation-free alternative to PET-CT for staging of lymphoma and other malignancies. [47] Hypercellular tumors show comparatively restricted water diffusion to normal tissues, which is reflected as high signal intensity on DWI with low apparent diffusion coefficient (ADC). DWI has a sensitivity of up to 97% and can be used as an alternative to PET-CT for follow-up and assessment of treatment response. [48, 49] The higher the magnetic field strength in DWI, the higher the signal-to-noise ratio.
Gadolinium-based contrast agents have been linked to the development of nephrogenic systemic fibrosis (NSF) or nephrogenic fibrosing dermopathy (NFD). The disease has occurred in patients with moderate to end-stage renal disease after being given a gadolinium-based contrast agent to enhance MRI or MRA scans. NSF/NFD is a debilitating and sometimes fatal disease. Characteristics include red or dark patches on the skin; burning, itching, swelling, hardening, and tightening of the skin; yellow spots on the whites of the eyes; joint stiffness with trouble moving or straightening the arms, hands, legs, or feet; pain deep in the hip bones or ribs; and muscle weakness.
As with the criteria used in CT, a lymph node larger than 1.0 cm can be reactive without tumor involvement. Lymph nodes smaller than those that fall within the size criteria can also harbor disease. [29]
MRI is more sensitive for detecting bone marrow involvement associated with lymphoma. [46]
False-positive findings can result from residual lymph node masses that may not harbor any disease. To evaluate this possibility further, gallium scanning and PET scanning can help.
Radiation-induced inflammatory changes can result in increased signal intensity on T2-weighted images. These changes can mimic active disease.
Ultrasonography can help in performing mediastinal biopsies, but it is primarily used for the evaluation and biopsy of lesions involving the chest wall. Echocardiography is useful for the detection of clinically undetectable pericardial disease. [4, 10, 50, 51, 52]
Ultrasonography cannot help in differentiating the causes of pericardial effusion (eg, malignant, radiation-induced, drug-induced, or idiopathic effusion).
An echocardiogram can be used for determination of left ventricular ejection fraction before and after chemotherapy.
Gallium-67 citrate scintigraphy (GS) has been shown to provide important diagnostic and prognostic information in patients with lymphoma. In Hodgkin disease, GS provides additional information in conjunction with CT for planning radiation therapy. GS is helpful for distinguishing residual disease from posttreatment fibrosis in bulky mediastinal Hodgkin disease. [43, 53, 54, 55]
Posttreatment 67Ga uptake is a poor prognostic factor in Hodgkin disease and non–Hodgkin lymphoma, and it is an accurate predictor of the patient’s response to therapy and the overall outcome. In patients with aggressive lesions, advanced – stage tumors, or difficult-to-treat cases, sequential gallium scintigraphy can be performed before, during, or after therapy. These studies help in understanding the gallium avidity of the tumor, the response of tumor to therapy, and the timing of the therapeutic response. [43, 44, 53, 54, 55, 56]
Gallium uptake in tumor cells is mediated by transferrin receptors, and binding to cell-surface transferrin receptors allows this complex to be taken by actively growing tumor cells. Radiation therapy results in transient or permanent loss of 67Ga uptake, although recurrent Hodgkin disease is invariably associated with the return of increased uptake. [54, 55, 56, 57]
In Hodgkin disease, the sensitivity of GS is 85-97% and the specificity is 90-100%. Use of high-dose GS and single-photon emission CT (SPECT) techniques has increased the sensitivity of GS, especially for evaluating the mediastinum and abdomen. [56, 58]
FDG PET-CT is crucial for initial staging and evaluation of treatment response in Hodgkin disease. PET-CT often leads to either upstaging or downstaging in approximately 15-40% of patients with Hodgkin lymphoma and, as a result, a change in management in 5-15% of patients. [59, 60] A negative PET study reliably rules out Hodgkin relapse; however, the positive predictive value of PET is variable and thus cannot reliably diagnose a relapse. A biopsy is therefore necessary. [61] FDG PET-CT is extremely useful in radiation treatment planning by helping better map the radiation fields without increasing radiation volumes. [62] FDG PET-CT has limitations, as FDG uptake can be seen in posttreatment inflammation, infection, brown fat, and normal physiologic metabolic activity, leading to false positive results. False negative results can be seen in low-grade histologic subtypes, as well as in minimal residual disease. [63]
Uptake of FDG is increased in malignant cells compared with normal tissues because of a patient’s altered metabolism during malignancy (in which glycolysis becomes the major metabolic pathway). [13, 42, 44, 64, 15, 16, 65] Several studies have suggested that FDG scintigraphy is as good as CT for staging lymphomas. Moog et al showed that FDG PET is superior to CT in staging nodal lymphoma. [66, 67]
Bangerter et al found that for detecting hilar and mediastinal sites of disease before treatment, the sensitivity of FDG PET is 98% and the specificity is 90%, while the positive predictive value is 92% and the negative predictive value is 97%. [68]
FDG PET studies may cause upstaging of the disease because of bone marrow involvement. These studies can be used to guide targeted MRI scans and bone marrow biopsies. FDG PET can also help in characterizing residual masses after therapy, when morphologic imaging modalities are of limited value. PET can be used in the detection of relapse, and Bangerter et al found a sensitivity of 86% and a specificity of 96% for the detection of recurrent disease in mediastinal and hilar nodes in patients with lymphoma. [68]
A multigated acquisition (MUGA) scan can be used for exact determination of ejection fraction.
For GS, a posttreatment FDG PET scan with negative findings has a negative predictive value of 100%, but positive scans have a positive predictive value of only 61%.
Gallium uptake is nonspecific, and uptake can be seen in various tumors, inflammation, and infection; however, in a known setting of Hodgkin disease, any abnormal uptake should be viewed as active disease, residual disease, or recurrence (see the image below).
Angiography does not have much of a role in the diagnosis and management of Hodgkin disease, but superior venacavography is performed in patients believed to have SVC syndrome. This is achieved mainly via CT venography rather with superior venocavography.
Mann RB, Jaffe ES, Berard CW. Malignant lymphomas–a conceptual understanding of morphologic diversity. A review. Am J Pathol. 1979 Jan. 94(1):105-91. [Medline].
Strickler JG, Kurtin PJ. Mediastinal lymphoma. Semin Diagn Pathol. 1991 Feb. 8(1):2-13. [Medline].
Hodgkin T. On Some Morbid Appearances of the Absorbent Glands and Spleen. Medico-Chir. Trans. 1832. 17:68-114.
Toma P, Granata C, Rossi A, Garaventa A. Multimodality imaging of Hodgkin disease and non-Hodgkin lymphomas in children. Radiographics. 2007 Sep-Oct. 27(5):1335-54. [Medline].
What are the key statistics about Hodgkin disease?. American Cancer Society. Available at http://www.cancer.org/cancer/hodgkindisease/detailedguide/hodgkin-disease-key-statistics. 2016 Feb 9; Accessed: Oct.16, 2016.
Ellert J, Kreel L. The role of computed tomography in the initial staging and subsequent management of the lymphomas. J Comput Assist Tomogr. 1980 Jun. 4(3):368-91. [Medline].
Rostock RA, Giangreco A, Wharam MD, Lenhard R, Siegelman SS, Order SE. CT scan modification in the treatment of mediastinal Hodgkin’s disease. Cancer. 1982 Jun 1. 49(11):2267-75. [Medline].
Kriz J, Mueller RP, Mueller H, Kuhnert G, Engert A, Kobe C, et al. Large mediastinal tumor mass as a prognostic factor in Hodgkin’s lymphoma. Is the definition on the basis of a chest radiograph in the era of CT obsolete?. Strahlenther Onkol. 2012 Nov. 188(11):1020-4. [Medline].
Uehara M, Takahashi J, Hirabayashi H, Kitahara J, Kamijyo T, Ebara S, et al. Hodgkin’s disease of the thoracic vertebrae. Spine J. 2013 Aug. 13(8):e59-63. [Medline].
Saito T, Kobayashi H, Sugama Y, et al. Ultrasonically guided needle biopsy in the diagnosis of mediastinal masses. Am Rev Respir Dis. 1988 Sep. 138(3):679-84. [Medline].
Langley CR, Garrett SJ, Urand J, Kohler J, Clarke NM. Primary multifocal osseous Hodgkin’s lymphoma. World J Surg Oncol. 2008 Mar 17. 6:34. [Medline].
Cremerius U, Fabry U, Neuerburg J, et al. Positron emission tomography with 18F-FDG to detect residual disease after therapy for malignant lymphoma. Nucl Med Commun. 1998 Nov. 19(11):1055-63. [Medline].
De Wit M, Bumann D, Beyer W, et al. Whole-body positron emission tomography (PET) for diagnosis of residual mass in patients with lymphoma. Ann Oncol. 8 Suppl 1:57-60. [Medline].
Fallanca F, Picchio M, Crivellaro C, Mapelli P, Samanes Gajate AM, Sabattini E, et al. Unusual presentation of sarcoid-like reaction on bone marrow level associated with mediastinal lymphadenopathy on (18)F-FDG-PET/CT resembling an early recurrence of Hodgkin’s Lymphoma. Rev Esp Med Nucl Imagen Mol. 2012 Jul-Aug. 31(4):207-9. [Medline].
Jorgov L, Montravers F, Balogova S, Ragu C, Pacquement H, Leblanc T, et al. Paediatric and adolescent Hodgkin lymphoma: information derived from diffuse organ uptake of 18 F-fluorodeoxyglucose on pre-treatment and on interim PET/CT. Eur J Nucl Med Mol Imaging. 2016 Jul. 43 (7):1220-30. [Medline].
Taralli S, Leccisotti L, Mattoli MV, Castaldi P, de Waure C, Mancuso A, et al. Physiological Activity of Spinal Cord in Children: An 18F-FDG PET-CT Study. Spine (Phila Pa 1976). 2015 Jun 1. 40 (11):E647-52. [Medline].
Munker R, Hasenclever D, Brosteanu O, Hiller E, Diehl V. Bone marrow involvement in Hodgkin’s disease: an analysis of 135 consecutive cases. German Hodgkin’s Lymphoma Study Group. J Clin Oncol. 1995 Feb. 13(2):403-9. [Medline].
Elkowitz SS, Leonidas JC, Lopez M, et al. Comparison of CT and MRI in the evaluation of therapeutic response in thoracic Hodgkin disease. Pediatr Radiol. 1993. 23(4):301-4. [Medline].
Kaesberg PR, Foley DB, Pellett J, Hafez GR, Ershler WB. Concurrent development of a thymic cyst and mediastinal Hodgkin’s disease. Med Pediatr Oncol. 1988. 16(4):293-4. [Medline].
Keller AR, Castleman B. Hodgkin’s disease of the thymus gland. Cancer. 1974 Jun. 33(6):1615-23. [Medline].
Keller AR, Kaplan HS, Lukes RJ, Rappaport H. Correlation of histopathology with other prognostic indicators in Hodgkin’s disease. Cancer. 1968 Sep. 22(3):487-99. [Medline].
Kennedy BJ, Loeb V Jr, Peterson V, Donegan W, Natarajan N, Mettlin C. Survival in Hodgkin’s disease by stage and age. Med Pediatr Oncol. 1992. 20(2):100-4. [Medline].
Kim HC, Nosher J, Haas A, Sweeney W, Lewis R. Cystic degeneration of thymic Hodgkin’s disease following radiation therapy. Cancer. 1985 Jan 15. 55(2):354-6. [Medline].
Schomberg PJ, Evans RG, O’Connell MJ, White WL, Banks PM, Ilstrup DM, et al. Prognostic significance of mediastinal mass in adult Hodgkin’s disease. Cancer. 1984 Jan 15. 53(2):324-8. [Medline].
Lister TA, Crowther D, Sutcliffe SB, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin’s disease: Cotswolds meeting. J Clin Oncol. 1989 Nov. 7(11):1630-6. [Medline].
Bradley AJ, Carrington BM, Lawrance JA, et al. Assessment and significance of mediastinal bulk in Hodgkin’s disease: comparison between computed tomography and chest radiography. J Clin Oncol. 1999 Aug. 17(8):2493-8. [Medline].
Panicek DM, Harty MP, Scicutella CJ, Carsky EW. Calcification in untreated mediastinal lymphoma. Radiology. 1988 Mar. 166(3):735-6. [Medline].
Filly R, Bland N, Castellino RA. Radiographic distribution of intrathoracic disease in previously untreated patients with Hodgkin’s disease and non-Hodgkin’s lymphoma. Radiology. 1976 Aug. 120(2):277-81. [Medline].
Bradley AJ, Carrington BM, Lawrance JA, Ryder WD, Radford JA. Assessment and significance of mediastinal bulk in Hodgkin’s disease: comparison between computed tomography and chest radiography. J Clin Oncol. 1999 Aug. 17(8):2493-8. [Medline].
Castellino RA, Blank N, Hoppe RT, Cho C. Hodgkin disease: contributions of chest CT in the initial staging evaluation. Radiology. 1986 Sep. 160(3):603-5. [Medline].
Hopper KD, Diehl LF, Lesar M, et al. Hodgkin disease: clinical utility of CT in initial staging and treatment. Radiology. 1988 Oct. 169(1):17-22. [Medline].
Callen PW, Korobkin M, Isherwood I. Computed tomographic evaluation of the retrocrural prevertebral space. AJR Am J Roentgenol. 1977 Nov. 129(5):907-10. [Medline].
Dorfman RE, Alpern MB, Gross BH, Sandler MA. Upper abdominal lymph nodes: criteria for normal size determined with CT. Radiology. 1991 Aug. 180(2):319-22. [Medline].
Glazer GM, Gross BH, Quint LE, et al. Normal mediastinal lymph nodes: number and size according to American Thoracic Society mapping. AJR Am J Roentgenol. 1985 Feb. 144(2):261-5. [Medline].
Hopper KD, Diehl LF, Cole BA, et al. The significance of necrotic mediastinal lymph nodes on CT in patients with newly diagnosed Hodgkin disease. AJR Am J Roentgenol. 1990 Aug. 155(2):267-70. [Medline].
Vargas HA, Hampson FA, Babar JL, Shaw AS. Imaging the lungs in patients treated for lymphoma. Clin Radiol. 2009 Nov. 64 (11):1048-55. [Medline].
Choi YW, Munden RF, Erasmus JJ, Park KJ, Chung WK, Jeon SC, et al. Effects of radiation therapy on the lung: radiologic appearances and differential diagnosis. Radiographics. 2004 Jul-Aug. 24 (4):985-97; discussion 998. [Medline].
Park KJ, Chung JY, Chun MS, Suh JH. Radiation-induced lung disease and the impact of radiation methods on imaging features. Radiographics. 2000 Jan-Feb. 20 (1):83-98. [Medline].
Rossi SE, Erasmus JJ, McAdams HP, Sporn TA, Goodman PC. Pulmonary drug toxicity: radiologic and pathologic manifestations. Radiographics. 2000 Sep-Oct. 20 (5):1245-59. [Medline].
Cella L, Liuzzi R, D’Avino V, Conson M, Di Biase A, Picardi M, et al. Pulmonary damage in Hodgkin’s lymphoma patients treated with sequential chemo-radiotherapy: Predictors of radiation-induced lung injury. Acta Oncol. 2014 May. 53 (5):613-9. [Medline].
Carlsen SE, Bergin CJ, Hoppe RT. MR imaging to detect chest wall and pleural involvement in patients with lymphoma: effect on radiation therapy planning. AJR Am J Roentgenol. 1993 Jun. 160(6):1191-5. [Medline].
Carr R, Barrington SF, Madan B, et al. Detection of lymphoma in bone marrow by whole-body positron emission tomography. Blood. 1998 May 1. 91(9):3340-6. [Medline].
Hill M, Cunningham D, MacVicar D, et al. Role of magnetic resonance imaging in predicting relapse in residual masses after treatment of lymphoma. J Clin Oncol. 1993 Nov. 11(11):2273-8. [Medline].
Kostakoglu L, Goldsmith SJ. Fluorine-18 fluorodeoxyglucose positron emission tomography in the staging and follow-up of lymphoma: is it time to shift gears?. Eur J Nucl Med. 2000 Oct. 27(10):1564-78. [Medline].
Rahmouni A, Tempany C, Jones R, et al. Lymphoma: monitoring tumor size and signal intensity with MR imaging. Radiology. 1993 Aug. 188(2):445-51. [Medline].
Hoane BR, Shields AF, Porter BA, Borrow JW. Comparison of initial lymphoma staging using computed tomography (CT) and magnetic resonance (MR) imaging. Am J Hematol. 1994 Oct. 47(2):100-5. [Medline].
Mayerhoefer ME, Karanikas G, Kletter K, Prosch H, Kiesewetter B, Skrabs C, et al. Evaluation of diffusion-weighted MRI for pretherapeutic assessment and staging of lymphoma: results of a prospective study in 140 patients. Clin Cancer Res. 2014 Jun 1. 20 (11):2984-93. [Medline].
Stéphane V, Samuel B, Vincent D, Joelle G, Remy P, Francois GG, et al. Comparison of PET-CT and magnetic resonance diffusion weighted imaging with body suppression (DWIBS) for initial staging of malignant lymphomas. Eur J Radiol. 2013 Nov. 82 (11):2011-7. [Medline].
Mayerhoefer ME, Karanikas G, Kletter K, Prosch H, Kiesewetter B, Skrabs C, et al. Evaluation of Diffusion-Weighted Magnetic Resonance Imaging for Follow-up and Treatment Response Assessment of Lymphoma: Results of an 18F-FDG-PET/CT-Controlled Prospective Study in 64 Patients. Clin Cancer Res. 2015 Jun 1. 21 (11):2506-13. [Medline].
Rubens DJ, Strang JG, Fultz PJ, Gottlieb RH. Sonographic guidance of mediastinal biopsy: an effective alternative to CT guidance. AJR Am J Roentgenol. 1997 Dec. 169(6):1605-10. [Medline].
Yang PC, Chang DB, Lee YC, et al. Mediastinal malignancy: ultrasound guided biopsy through the supraclavicular approach. Thorax. 1992 May. 47(5):377-80. [Medline].
Wernecke K, Vassallo P, Peters PE, von Bassewitz DB. Mediastinal tumors: biopsy under US guidance. Radiology. 1989 Aug. 172(2):473-6. [Medline].
Front D, Ben-Haim S, Israel O, et al. Lymphoma: predictive value of Ga-67 scintigraphy after treatment. Radiology. 1992 Feb. 182(2):359-63. [Medline].
Israel O, Front D, Lam M, et al. Gallium 67 imaging in monitoring lymphoma response to treatment. Cancer. 1988 Jun 15. 61(12):2439-43. [Medline].
Jochelson MS, Herman TS, Stomper PC, et al. Planning mantle radiation therapy in patients with Hodgkin disease: role of gallium-67 scintigraphy. AJR Am J Roentgenol. 1988 Dec. 151(6):1229-31. [Medline].
Kaplan WD. Residual mass and negative gallium scintigraphy in treated lymphoma: when is the gallium scan really negative?. J Nucl Med. 1990 Mar. 31(3):369-71. [Medline].
Israel O, Front D, Epelbaum R, et al. Residual mass and negative gallium scintigraphy in treated lymphoma. J Nucl Med. 1990 Mar. 31(3):365-8. [Medline].
Wylie BR, Southee AE, Joshua DE, McLaughlin AF, Gibson J, Hutton BF, et al. Gallium scanning in the management of mediastinal Hodgkin’s disease. Eur J Haematol. 1989 Apr. 42(4):344-7. [Medline].
Bednaruk-Młyński E, Pieńkowska J, Skórzak A, Małkowski B, Kulikowski W, Subocz E, et al. Comparison of positron emission tomography/computed tomography with classical contrast-enhanced computed tomography in the initial staging of Hodgkin lymphoma. Leuk Lymphoma. 2015 Feb. 56 (2):377-82. [Medline].
Juweid ME. Utility of positron emission tomography (PET) scanning in managing patients with Hodgkin lymphoma. Hematology Am Soc Hematol Educ Program. 2006. 259-65, 510-1. [Medline].
El-Galaly TC, Mylam KJ, Brown P, Specht L, Christiansen I, Munksgaard L, et al. Positron emission tomography/computed tomography surveillance in patients with Hodgkin lymphoma in first remission has a low positive predictive value and high costs. Haematologica. 2012 Jun. 97 (6):931-6. [Medline].
Girinsky T, Aupérin A, Ribrag V, Elleuch M, Fermé C, Bonniaud G, et al. Role of FDG-PET in the implementation of involved-node radiation therapy for Hodgkin lymphoma patients. Int J Radiat Oncol Biol Phys. 2014 Aug 1. 89 (5):1047-52. [Medline].
McInnes MD, Kielar AZ, Macdonald DB. Percutaneous image-guided biopsy of the spleen: systematic review and meta-analysis of the complication rate and diagnostic accuracy. Radiology. 2011 Sep. 260 (3):699-708. [Medline].
Stumpe KD, Urbinelli M, Steinert HC, et al. Whole-body positron emission tomography using fluorodeoxyglucose for staging of lymphoma: effectiveness and comparison with computed tomography. Eur J Nucl Med. 1998 Jul. 25(7):721-8. [Medline].
Atkinson W, Catana C, Abramson JS, Arabasz G, McDermott S, Catalano O, et al. Hybrid FDG-PET/MR compared to FDG-PET/CT in adult lymphoma patients. Abdom Radiol (NY). 2016 Jul. 41 (7):1338-48. [Medline].
Moog F, Bangerter M, Kotzerke J, et al. 18-F-fluorodeoxyglucose-positron emission tomography as a new approach to detect lymphomatous bone marrow. J Clin Oncol. 1998 Feb. 16(2):603-9. [Medline].
Moog F, Bangerter M, Diederichs CG, et al. Lymphoma: role of whole-body 2-deoxy-2-[F-18]fluoro-D-glucose (FDG) PET in nodal staging. Radiology. 1997 Jun. 203(3):795-800. [Medline].
Bangerter M, Kotzerke J, Griesshammer M, et al. Positron emission tomography with 18-fluorodeoxyglucose in the staging and follow-up of lymphoma in the chest. Acta Oncol. 1999. 38(6):799-804. [Medline].
Narainder Gupta, MD, DRM, MSc, FRCR Associate Professor of Clinical Radiology, Perelman School of Medicine, University of Pennsylvania
Narainder Gupta, MD, DRM, MSc, FRCR is a member of the following medical societies: American College of Radiology, Radiological Society of North America, Society of Thoracic Radiology, Society of Cardiovascular Computed Tomography
Disclosure: Nothing to disclose.
Jamshed B Bomanji, MBBS, MSc, PhD, FRCR, FRCP Consulting Staff, Institute of Nuclear Medicine, Middlesex Hospital; Nuclear Medicine Consultant, University College Hospital
Jamshed B Bomanji, MBBS, MSc, PhD, FRCR, FRCP is a member of the following medical societies: British Medical Association, Society of Nuclear Medicine and Molecular Imaging, Medical Protection Society
Disclosure: Nothing to disclose.
Bernard D Coombs, MB, ChB, PhD Consulting Staff, Department of Specialist Rehabilitation Services, Hutt Valley District Health Board, New Zealand
Disclosure: Nothing to disclose.
Eugene C Lin, MD Attending Radiologist, Teaching Coordinator for Cardiac Imaging, Radiology Residency Program, Virginia Mason Medical Center; Clinical Assistant Professor of Radiology, University of Washington School of Medicine
Eugene C Lin, MD is a member of the following medical societies: American College of Nuclear Medicine, American College of Radiology, Radiological Society of North America, Society of Nuclear Medicine and Molecular Imaging
Disclosure: Nothing to disclose.
Kitt Shaffer, MD, PhD
Kitt Shaffer, MD, PhD is a member of the following medical societies: American Roentgen Ray Society
Disclosure: Nothing to disclose.
Special thanks are extended to Dr. Jeremy Lawrance for his contributions to this topic.
Thoracic Hodgkin Disease Imaging
Research & References of Thoracic Hodgkin Disease Imaging|A&C Accounting And Tax Services
Source
0 Comments